[go: up one dir, main page]

MA38253A1 - Compositions comprenant de la vortioxétine et du donépézil - Google Patents

Compositions comprenant de la vortioxétine et du donépézil

Info

Publication number
MA38253A1
MA38253A1 MA38253A MA38253A MA38253A1 MA 38253 A1 MA38253 A1 MA 38253A1 MA 38253 A MA38253 A MA 38253A MA 38253 A MA38253 A MA 38253A MA 38253 A1 MA38253 A1 MA 38253A1
Authority
MA
Morocco
Prior art keywords
compositions
vortioxetine
donepezil
treatment
relates
Prior art date
Application number
MA38253A
Other languages
English (en)
Other versions
MA38253B1 (fr
Inventor
Connie Sanchez Morillo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA38253A1 publication Critical patent/MA38253A1/fr
Publication of MA38253B1 publication Critical patent/MA38253B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques comprenant de la vortioxétine et du donépézil, et l'utilisation de ces compositions pour le traitement de dysfonctionnements cognitifs.
MA38253A 2012-12-13 2013-12-12 Compositions comprenant de la vortioxétine et du donépézil MA38253B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13
PCT/EP2013/076337 WO2014090929A1 (fr) 2012-12-13 2013-12-12 Compositions comprenant de la vortioxétine et du donépézil

Publications (2)

Publication Number Publication Date
MA38253A1 true MA38253A1 (fr) 2017-02-28
MA38253B1 MA38253B1 (fr) 2017-10-31

Family

ID=49943326

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38253A MA38253B1 (fr) 2012-12-13 2013-12-12 Compositions comprenant de la vortioxétine et du donépézil

Country Status (44)

Country Link
US (1) US9211288B2 (fr)
EP (1) EP2931276B1 (fr)
JP (1) JP6257641B2 (fr)
KR (1) KR102171152B1 (fr)
CN (1) CN104853755B (fr)
AP (1) AP2015008498A0 (fr)
AR (2) AR093939A1 (fr)
AU (1) AU2013357308B2 (fr)
BR (1) BR112015013675B1 (fr)
CA (1) CA2893468C (fr)
CL (1) CL2015001615A1 (fr)
CR (1) CR20150303A (fr)
CY (1) CY1120098T1 (fr)
DK (1) DK2931276T3 (fr)
DO (1) DOP2015000133A (fr)
EA (1) EA028300B1 (fr)
EC (1) ECSP15023182A (fr)
ES (1) ES2663680T3 (fr)
GE (1) GEP201706739B (fr)
GT (1) GT201500143A (fr)
HR (1) HRP20180333T1 (fr)
HU (1) HUE036280T2 (fr)
IL (1) IL239192B (fr)
LT (1) LT2931276T (fr)
MA (1) MA38253B1 (fr)
ME (1) ME03029B (fr)
MX (1) MX362886B (fr)
MY (1) MY171802A (fr)
NI (1) NI201500078A (fr)
NO (1) NO2970700T3 (fr)
NZ (1) NZ708595A (fr)
PE (1) PE20151026A1 (fr)
PH (1) PH12015501302B1 (fr)
PL (1) PL2931276T3 (fr)
PT (1) PT2931276T (fr)
RS (1) RS56949B1 (fr)
RU (1) RU2635528C2 (fr)
SG (1) SG11201504483YA (fr)
SI (1) SI2931276T1 (fr)
SM (1) SMT201800135T1 (fr)
TN (1) TN2015000235A1 (fr)
UA (1) UA114016C2 (fr)
WO (1) WO2014090929A1 (fr)
ZA (1) ZA201504274B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
CN108348486A (zh) * 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
AU2017288456A1 (en) 2016-07-01 2018-12-13 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US20190216803A1 (en) 2017-03-30 2019-07-18 Rundle Research, LLC Methods of treating depression with vortioxetine
PL3528811T3 (pl) 2017-03-30 2022-01-10 Rundle Research, LLC Wortioksetyna i inhibitory mao do leczenia depresji
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression
WO2020087031A1 (fr) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268871A1 (fr) 1986-10-31 1988-06-01 Sumitomo Pharmaceuticals Company, Limited Dérivés de quinoléine
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
EP0403713A1 (fr) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'acétylcholinestérase
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (fr) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
ES2165586T3 (es) 1996-04-12 2002-03-16 Aventis Pharma Inc Derivados de isatina como inhibidores de acetilcolinesterasa y analgesicos.
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP4405811B2 (ja) 2002-03-29 2010-01-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 （１−インダノン）−（１，２，３，６−テトラヒドロピリジン）誘導体
DE60324788D1 (de) * 2002-05-31 2009-01-02 Lundbeck & Co As H Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
AU2003291910B2 (en) * 2002-12-24 2009-10-01 Bellus Health (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
AU2006343077B2 (en) * 2006-05-08 2012-11-08 Teikoku Seiyaku Co., Ltd. Tansdermally absorbable preparation comprising anti-dementia agent
WO2007146073A2 (fr) * 2006-06-09 2007-12-21 Wyeth Procédé destiné à renforcer la fonction cognitive
ZA200810017B (en) * 2006-06-16 2010-04-28 Lundbeck & Co As H 1- [2- (2, 4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin Reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
WO2009005519A1 (fr) * 2007-06-29 2009-01-08 Accera, Inc. Combinaisons de triglycérides à chaîne moyenne et d'agents thérapeutiques pour le traitement et la prévention de la maladie d'alzheimer et d'autres maladies résultant d'un métabolisme neuronal réduit
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
DOP2015000133A (es) 2015-11-30
TN2015000235A1 (en) 2016-10-03
RU2015122256A (ru) 2017-01-16
AR125920A2 (es) 2023-08-23
AR093939A1 (es) 2015-07-01
HK1212601A1 (en) 2016-06-17
MA38253B1 (fr) 2017-10-31
HUE036280T2 (hu) 2018-06-28
EA201590932A1 (ru) 2015-10-30
BR112015013675A2 (pt) 2017-07-11
IL239192B (en) 2019-03-31
PT2931276T (pt) 2018-03-19
HRP20180333T1 (hr) 2018-04-06
KR102171152B1 (ko) 2020-10-29
AU2013357308B2 (en) 2017-08-31
MY171802A (en) 2019-10-30
US20150297585A1 (en) 2015-10-22
IL239192A0 (en) 2015-07-30
UA114016C2 (xx) 2017-04-10
ECSP15023182A (es) 2015-12-31
CA2893468A1 (fr) 2014-06-19
CL2015001615A1 (es) 2015-08-07
AP2015008498A0 (en) 2015-05-31
CR20150303A (es) 2016-07-07
ZA201504274B (en) 2016-11-30
NO2970700T3 (fr) 2018-05-26
RS56949B1 (sr) 2018-05-31
EP2931276A1 (fr) 2015-10-21
WO2014090929A1 (fr) 2014-06-19
KR20150095681A (ko) 2015-08-21
EP2931276B1 (fr) 2018-02-21
MX2015007269A (es) 2015-08-12
CA2893468C (fr) 2021-01-12
PL2931276T3 (pl) 2018-06-29
ES2663680T3 (es) 2018-04-16
MX362886B (es) 2019-02-22
PH12015501302A1 (en) 2016-02-01
NI201500078A (es) 2016-02-15
DK2931276T3 (en) 2018-03-26
RU2635528C2 (ru) 2017-11-13
GT201500143A (es) 2016-01-22
SI2931276T1 (en) 2018-05-31
SMT201800135T1 (it) 2018-05-02
PE20151026A1 (es) 2015-07-11
CN104853755B (zh) 2017-08-22
BR112015013675B1 (pt) 2022-04-26
CN104853755A (zh) 2015-08-19
JP6257641B2 (ja) 2018-01-10
GEP201706739B (en) 2017-09-25
LT2931276T (lt) 2018-04-10
AU2013357308A1 (en) 2015-06-18
NZ708595A (en) 2019-06-28
SG11201504483YA (en) 2015-07-30
ME03029B (fr) 2018-10-20
JP2016502990A (ja) 2016-02-01
US9211288B2 (en) 2015-12-15
PH12015501302B1 (en) 2016-02-01
CY1120098T1 (el) 2018-12-12
EA028300B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA41013A (fr) Compositions comprenant des souches bactériennes
EP2828247A4 (fr) Composés pour le traitement de l'amyotrophie spinale
EP2819519A4 (fr) Composés pour le traitement de l'amyotrophie spinale
EP2914277A4 (fr) Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres
EP2872151A4 (fr) Compositions pro-tolérogènes acellulaires pour le traitement ou la prévention de maladies auto-immunes
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
EP2931268A4 (fr) Compositions de gamma-hydroxybutyrate et leur utilisation pour le traitement de troubles
EP3222278C0 (fr) Utilisation de l'azelnidipine pour la préparation d'une composition pharmaceutique indiquée pour le traitement du cancer
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EP2916860A4 (fr) Composition pour le traitement du diabète ou de la diabésité comprenant un analogue d'oxyntomoduline
EP4414376A3 (fr) Nouveau depsipeptide et ses utilisations
MY193728A (en) Muscarinic receptor agonists
EP2875826A4 (fr) Composition pour la prévention ou le traitement d'une sepsie
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EP2786758A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de troubles des fonctions cognitives comprenant de la spinosyne
EA201792575A1 (ru) Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP2890370A4 (fr) Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
EA201791009A1 (ru) Композиции, содержащие циклоспорин
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine